The data on male health in industrialized countries over the past 40 years is, in aggregate, alarming. Testosterone levels have declined. Sperm counts have declined. Rates of depression, suicide, obesity, metabolic syndrome, and infertility have all increased. Life expectancy — which improved consistently through most of the 20th century — has stagnated or declined in some male populations. Researchers have been identifying the individual data points for decades; what is now becoming clear is that these trends are related, and hormonal decline is a central thread connecting them.
The Testosterone Decline: Epidemiological Evidence
The Massachusetts Male Aging Study — a longitudinal cohort that has followed Massachusetts men since 1987 — provided the first population-level evidence of cohort-based testosterone decline independent of aging. Men born later had lower testosterone levels at equivalent ages than men born earlier, after full adjustment for age, BMI, and health status. The magnitude: approximately 1–1.5% per year, translating to about 25% lower testosterone in men today compared to men of the same age in 1987.
This decline has been replicated in multiple countries — Denmark, Finland, the US, South Korea — suggesting a shared environmental or lifestyle driver rather than a country-specific phenomenon. The most investigated candidates include: endocrine-disrupting chemicals (particularly phthalates and bisphenol A in plastics, which displace testosterone at androgen receptors and directly suppress testicular function), declining physical activity (muscle mass is directly correlated with testosterone through multiple feedback mechanisms), rising obesity rates (adipose tissue converts testosterone to estrogen through aromatase activity), and increasing chronic psychological stress and sleep disruption (both directly suppress the HPG axis).
The Sperm Count Crisis
A 2022 update to the landmark 2017 meta-analysis by Levine et al. found that sperm concentration in Western men had declined 62% between 1973 and 2018 — with the rate of decline accelerating after 2000. This is not attributable to age or methodological changes in measurement. The researchers found the same trend in non-Western men, suggesting a global phenomenon.
Mental Health and Testosterone
The relationship between testosterone and mental health in men is robust and bidirectional. Low testosterone is an independent risk factor for depression — not mediated by comorbidities, not explained by low energy or reduced libido, but a direct neurochemical effect through testosterone's modulation of serotonin, dopamine, and GABA systems. The alarming rates of male depression and suicide in recent decades are occurring against a background of population-level testosterone decline and should be considered in that context.
The TRAVERSE Trial and Clinical Implications
The TRAVERSE trial — published in NEJM in 2023 — provided the long-awaited safety data on testosterone replacement therapy in older men with hypogonadism. The primary cardiovascular safety finding was reassuring: no increase in major adverse cardiovascular events with TRT. This should accelerate treatment of the millions of men with documented hypogonadism who have been undertreated due to cardiovascular safety concerns that were not supported by evidence.
The broader implication is harder to address with individual clinical intervention — it requires attention to the environmental drivers of population-level testosterone decline. Reducing plastic packaging exposure, addressing endocrine disruptor contamination of food and water, and creating social conditions that allow men to maintain the metabolic health, sleep quality, and stress management that support normal testosterone production are public health challenges that extend far beyond the clinic.